The UK and US have concluded a key trade agreement that will guarantee no tariffs on UK medicine exports being sold in the American market.
Key Provisions of the Accord
Under the terms of the agreement, the UK has pledged to boost expenditure on medicines through the NHS. This move guarantees that import taxes on these key products will be held at zero for a period of the next three years.
This deal comes after earlier statements to significantly raise import taxes on patented drug imports, with potential rates mentioned up to one hundred percent.
"This agreement between the UK reinforces the worldwide climate for innovative medicines and establishes much-needed equity to American-British medicine commerce," a statement declared.
Commercial Significance
Pharmaceuticals constitute one of the Britain's biggest goods shipped to the America, which is clearly the biggest destination for leading companies like GSK and AstraZeneca.
Trade data indicate that in the year prior to the third quarter, the UK exported drugs valued at over eleven billion pounds to the US. This amount accounted for 17.4% of total UK exports in that period.
"This deal secures work, increases funding and facilitates the UK to establish itself as a global hub for medical research," a minister commented.
Key British Pledges
The agreement involves several key changes from the United Kingdom:
- Higher Cost Ceiling: The UK will increase the affordability limit at which it judges new therapies to be prohibitively costly by 25%.
- Higher Drug Budget: There is a target to raise total NHS spending on medicines from 0.3% of GDP to 0.6% over the next decade.
- Refund Ceiling: The percentage pharmaceutical firms must return to the NHS to prevent overspending will be limited at fifteen percent. In the past, rebates exceeded 20%.
Broader Context
The deal follows a protracted tension between the drug companies and the British authorities over medicine costs and approval rates.
This friction were intensified by assertions that American consumers were charged a premium for the equivalent treatments than patients in the Britain and the EU.
Recently, several major manufacturing plans in the UK have been halted or abandoned, while major investments have been directed toward American operations.
A senior figure publicly accepted that the NHS needed to invest a greater share on drugs, noting that its expenditure on drugs had shrunk as a share of its overall budget over the previous ten-year period.
